Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025314 | 0.76 | NEK1 (0.54) | NEK1NR3C1MMP2MMP9NR3C2 | |
| SCHEMBL10073848 | 0.75 | KMT2A (0.35) | NEK1 | |
| SCHEMBL4647445 | 0.75 | NEK1 (0.65) | NEK1NR3C1MMP2MMP9NR3C2 | |
| SCHEMBL7141920 | 0.75 | NEK1 (0.55) | NEK1NR3C1MMP2MMP9NR3C2 | |
| SCHEMBL4649023 | 0.75 | NEK1 (0.55) | NEK1NR3C1MMP2MMP9NR3C2 | |
| SCHEMBL10073159 | 0.74 | ALDH1A1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL10072917 | 0.73 | GCK (0.36) | NEK1 | |
| SCHEMBL3128254 | 0.73 | NR3C1 (0.74) | NEK1NR3C1NR3C2PGR | |
| SCHEMBL10073652 | 0.73 | ALDH1A1 (0.33) | NR3C1 | |
| SCHEMBL3127701 | 0.72 | NR3C1 (0.75) | NEK1NR3C1MMP2MMP9NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445681-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | PRKDC, MAP3K20, PRKACA | NEK1 243/4885NR3C1 1508/4885MMP2 4054/4885 |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | PRKDC, MAP3K20, PRKACA | NEK1 243/4885NR3C1 1508/4885MMP2 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.